Media coverage about Aeglea BioTherapeutics (NASDAQ:AGLE) has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aeglea BioTherapeutics earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 47.5550872195437 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the news articles that may have impacted Accern’s rankings:

Separately, Zacks Investment Research upgraded Aeglea BioTherapeutics from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a research report on Thursday, August 3rd.

Aeglea BioTherapeutics (NASDAQ AGLE) opened at $4.82 on Tuesday. Aeglea BioTherapeutics has a 1 year low of $2.81 and a 1 year high of $10.34.

Aeglea BioTherapeutics (NASDAQ:AGLE) last posted its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.07. The firm had revenue of $1.26 million during the quarter. Aeglea BioTherapeutics had a negative return on equity of 44.05% and a negative net margin of 527.99%. sell-side analysts expect that Aeglea BioTherapeutics will post -1.97 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at

Aeglea BioTherapeutics Company Profile

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Insider Buying and Selling by Quarter for Aeglea BioTherapeutics (NASDAQ:AGLE)

Receive News & Ratings for Aeglea BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.